Following these findings, they initiated a phase I first-in-human study to monitor the safety, toxicity and Immunological response to vaccination in patients with CALR-mutant MPN vaccinated with a CALR exon 9 mutated peptide (ClinicalTrials.gov Identifier: NCT03566446). Here, CALR is linked to myeloproliferative neoplasm.